Literature DB >> 12663771

Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis.

Maryam Ahmed1, Margie O McKenzie, Shelby Puckett, Michael Hojnacki, Laurent Poliquin, Douglas S Lyles.   

Abstract

The vesicular stomatitis virus (VSV) matrix (M) protein plays a major role in the virus-induced inhibition of host gene expression. It has been proposed that the inhibition of host gene expression by M protein is responsible for suppressing activation of host interferon gene expression. Most wild-type (wt) strains of VSV induce little if any interferon gene expression. Interferon-inducing mutants of VSV have been isolated previously, many of which contain mutations in their M proteins. However, it was not known whether these M protein mutations were responsible for the interferon-inducing phenotype of these viruses. Alternatively, mutations in other genes besides the M gene may enhance the ability of VSV to induce interferons. These hypotheses were tested by transfecting cells with mRNA expressing wt and mutant M proteins in the absence of other viral components and determining their ability to inhibit interferon gene expression. The M protein mutations were the M51R mutation originally found in the tsO82 and T1026R1 mutant viruses, the double substitution V221F and S226R found in the TP3 mutant virus, and the triple substitution E213A, V221F, and S226R found in the TP2 mutant virus. wt M proteins suppressed expression of luciferase from the simian virus 40 promoter and from the beta interferon (IFN-beta) promoter, while M proteins of interferon-inducing viruses were unable to inhibit luciferase expression from either promoter. The M genes of the interferon-inducing mutants of VSV were incorporated into the wt background of a recombinant VSV infectious cDNA clone. The resulting recombinant viruses were tested for their ability to activate interferon gene expression and for their ability to inhibit host RNA and protein synthesis. Each of the recombinant viruses containing M protein mutations induced expression of a luciferase reporter gene driven by the IFN-beta promoter and induced production of interferon bioactivity more effectively than viruses containing wt M proteins. Furthermore, the M protein mutant viruses were defective in their ability to inhibit both host RNA synthesis and host protein synthesis. These data support the idea that wt M protein suppresses interferon gene expression through the general inhibition of host RNA and protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663771      PMCID: PMC152115          DOI: 10.1128/jvi.77.8.4646-4657.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98.

Authors:  J P Rodrigues; D Sitterlin; A Bachi; X Wu; M Wilm; M Carmo-Fonseca; E Izaurralde
Journal:  Mol Cell       Date:  2000-11       Impact factor: 17.970

2.  Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus.

Authors:  S A Kopecky; M C Willingham; D S Lyles
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Role of nucleoporin induction in releasing an mRNA nuclear export block.

Authors:  Jost Enninga; David E Levy; Günter Blobel; Beatriz M A Fontoura
Journal:  Science       Date:  2002-01-24       Impact factor: 47.728

4.  Inhibition of RNA synthesis in mouse myeloma cells infected with vesicular stomatitis virus.

Authors:  P K Weck; R R Wagner
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

5.  The matrix (M) protein of vesicular stomatitis virus regulates transcription.

Authors:  G M Clinton; S P Little; F S Hagen; A S Huang
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

6.  Inhibition of ribonucleic acid accumulation in mouse L cells infected with vesicular stomatitis virus requires viral ribonucleic acid transcription.

Authors:  F S Wu; J M Lucas-Lenard
Journal:  Biochemistry       Date:  1980-02-19       Impact factor: 3.162

7.  IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein.

Authors:  E J Smith; I Marié; A Prakash; A García-Sastre; D E Levy
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

8.  Inhibition of host transcription by vesicular stomatitis virus involves a novel mechanism that is independent of phosphorylation of TATA-binding protein (TBP) or association of TBP with TBP-associated factor subunits.

Authors:  H Yuan; S Puckett; D S Lyles
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.

Authors:  John H Connor; Douglas S Lyles
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.

Authors:  R N Harty; M E Brown; J P McGettigan; G Wang; H R Jayakar; J M Huibregtse; M A Whitt; M J Schnell
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more
  125 in total

1.  Combining mathematics and empirical data to predict emergence of RNA viruses that differ in reservoir use.

Authors:  C Brandon Ogbunugafor; Sanjay Basu; Nadya M Morales; Paul E Turner
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

2.  Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.

Authors:  M Ahmed; S Puckett; D S Lyles
Journal:  Cancer Gene Ther       Date:  2010-08-20       Impact factor: 5.987

3.  DISTINCT MECHANISMS OF INHIBITION OF VSV REPLICATION IN NEURONS MEDIATED BY TYPE I AND TYPE II IFN.

Authors:  Paul M D'Agostino; Jingjun Yang; Carol Shoshkes Reiss
Journal:  Virus Rev Res       Date:  2009-01-01

Review 4.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

5.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

6.  Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Marshall Behrens; Rebecca Nace; Shruthi Naik; Mark J Federspiel; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2016-09-26       Impact factor: 11.454

7.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.

Authors:  Maryam Ahmed; Latoya M Mitchell; Shelby Puckett; Kristina L Brzoza-Lewis; Douglas S Lyles; Elizabeth M Hiltbold
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription.

Authors:  Agnès Billecocq; Martin Spiegel; Pierre Vialat; Alain Kohl; Friedemann Weber; Michèle Bouloy; Otto Haller
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.